RCS - OptiBiotix Health - SlimBiome® study in European Journal of Nutrition

OptiBiotix HealthAnnouncement

11/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250611:nRSK2784Ma&default-theme=true

RNS Number : 2784M  OptiBiotix Health PLC  11 June 2025

 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

New SlimBiome® study published in European Journal of Nutrition

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
products which reduce hunger and food cravings, enhance the gut microbiome,
and sweet fibres as healthy sugar substitutes, announces the publication of a
new peer-reviewed study (https://rdcu.be/eqivT) on SlimBiome® in the European
Journal of Nutrition.  The European Journal of Nutrition is a peer reviewed,
international journal that has a high impact factor with its articles widely
cited and influential in its field.

 

The double-blind placebo-controlled study, led by Adele Costabile, Professor
of Clinical Nutrition and the Microbiome at the University of Roehampton,
found a single 3g dose of SlimBiome significantly reduced insulin levels,
hunger, and the desire to eat whilst increasing the feeling of fullness. These
are key factors in appetite regulation and the study conclusion highlights the
potential of SlimBiome® as a non-pharmaceutical  approach to weight
management. Prof Costabile will present her findings at the
(https://prebioticassociation.org/event/18th-international-scientific-conference-on-probiotics-prebiotics-gut-microbiota-and-health-ipc2025/)
18th International Scientific Conference on Probiotics, Prebiotics, Gut
Microbiota and Health being held on  24-26 June 2025.
(https://probiotic-conference.net/)

 

These findings on the impact of a single dose of SlimBiome® are consistent
with other published studies, consumer studies, and customer feedback which
have shown SlimBiome® reduces hunger and food cravings leading to users both
reducing the amount of food and the type of food they eat, leading to more
sustainable weight management.

 

The study was carried out to support health claims for appetite regulation and
hunger control in products of one of the USA's leading weight management
brands (see announcement on 15 April 2025). Scientifically substantiated
health claims help to differentiate SlimBiome® from other products on the
market. OptiBiotix now has acute and long-term studies in healthy, overweight,
and obese individuals which have allowed the Company to make on pack health
claims in Europe, Australia/New Zealand, India, Asia, Canada, and the USA
leading to agreements and multiple product launches with major international
and national companies and brands (e.g Morepen, Muscletech, Myprotein). In the
changing landscape of this market, brought about by the anti-obesity drugs,
traditional approaches to weight management are being replaced by science
backed products which provide functional benefits such as reduced hunger and
desire to eat. SlimBiome® meets this developing trend.

 

The University of Roehampton has published a press release which is set out
below in Appendix I.

 

Stephen O'Hara, CEO of OptiBiotix Health plc commented: "We are really pleased
to see this study published in such a well-respected journal.  The study adds
further evidence to demonstrate the efficacy of SlimBiome® in reducing hunger
and food cravings leading to changes in the amount and type of food people
eat. Whilst the anti-obesity drugs have strong risk-benefits in the 16%* of
the world adult population who are obese, they may not be the best choice for
the 43%* who are overweight. SlimBiome® represents a natural alternative,
particularly for overweight individuals, and has been widely used with no
reported adverse side effects".

*See WHO report  Obesity and overweight
(https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman                                        Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Peterhouse Capital Limited (Broker)  Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd
 Anna Dunphy                          Mob: 07876 741 001

 

 

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

 

Appendix I

 

 

New Research by the University of Roehampton

 

New study suggests there may be another option to anti-obesity drugs

 

A new peer-reviewed study (https://rdcu.be/eqivT) published today (10 June
2025) in the European Journal of Nutrition has found that a mineral-enriched
prebiotic fibre complex may offer a safe and effective alternative for
individuals seeking to manage their weight.

 

While anti-obesity medications can be effective for those with clinical
obesity, they often come with significant side effects and were developed for
cases where the risk-benefit trade-off is more clearly justified. For
individuals who fall into the overweight or high-normal BMI range, this
supplement could provide a better, non-pharmaceutical option for supporting
healthy weight management.

 

The study, led by Adele Costabile
(https://pure.roehampton.ac.uk/portal/en/persons/adele-costabile) , Professor
in Clinical Nutrition and the Microbiome at the University of Roehampton
(https://www.roehampton.ac.uk/) , found that the mineral-enriched fibre
supplement known as SlimBiome(®) significantly reduced post-meal insulin
levels, decreased hunger by up to 37%, and increased feelings of fullness by
up to 55% in healthy adults.

 

In a double-blind, placebo-controlled, randomised crossover trial,
normal-weight participants were given either the supplement or a standard
dextrose drink. The results were striking: participants who consumed the fibre
complex reported significantly lower hunger (p=0.038), reduced desire to eat
(p=0.002), and greater satiety (p=0.021) for over two hours post-ingestion
compared to the placebo. They also showed a marked reduction in insulin levels
at 45, 75, and 90 minutes after a glucose load, suggesting the supplement may
help regulate metabolic responses to food. These factors are important in
managing calorie intake.

 

Prof Costabile will present her findings at the
(https://prebioticassociation.org/event/18th-international-scientific-conference-on-probiotics-prebiotics-gut-microbiota-and-health-ipc2025/)
18th International Scientific Conference on Probiotics, Prebiotics, Gut
Microbiota and Health - IPC2025, 24-26 June 2025.
(https://probiotic-conference.net/)

 

With
(https://www.gov.uk/government/statistics/obesity-profile-may-2025-update)
64.5% of adults in England
(https://www.gov.uk/government/statistics/obesity-profile-may-2025-update) now
classified as overweight or obese - a 22.6% increase since 2015 - and
weight-related conditions including type 2 diabetes, heart disease and some
cancers placing a growing burden on the NHS, the search for sustainable,
non-pharmaceutical weight management tools is increasingly urgent.

 

"Most diets rely on willpower alone and often fail," said Professor Costabile.
"Our studies show that SlimBiome, a mineral-enriched prebiotic fibre complex,
can reduce hunger and food cravings, offering a natural and scientifically
backed option to anti-obesity drugs. Appetite regulation is a crucial part of
weight control, and this supplement may help improve long-term success without
harsh side effects."

 

The SlimBiome formulation, developed and patented by OptiBiotix Health,
combines glucomannan (a viscous plant fibre), fructooligosaccharides (FOS, a
prebiotic), and chromium (a trace mineral involved in insulin signalling) to
target multiple mechanisms. These include delayed gastric emptying, improved
blood sugar control, and gut microbiome modulation - factors that collectively
contribute to appetite regulation and metabolic health.

 

"While further studies are needed to assess long-term outcomes, our findings
indicate that combining fibre, prebiotics and trace minerals can support
healthy weight management and glycaemic control - without risking losing
muscle mass or causing gastrointestinal distress", said Professor Costabile.
"In fact, participants only lost fat, not muscle mass, and showed improvements
in gut microbiome diversity - including increases in beneficial bacteria known
to influence satiety signals."

 

The combination of the three key ingredients is unique. Glucomannan, a
plant-based fibre, acts to form a viscous gel in the stomach, slowing
digestion and carbohydrate absorption. FOS supports the growth of beneficial
gut bacteria, such as Bifidobacterium spp., which are known to promote the
release of short-chain fatty acids that influence appetite-regulating
hormones. Chromium, a trace mineral known to play a role in insulin
signalling, acts in combination with the other minerals to moderate insulin
responses.

 

Co-investigator of the studies, Dr. Michael Patterson of the University of
Roehampton, said: "Pharmaceuticals that mimic appetite-suppressing gut
hormones are a major advance, but not everyone can tolerate them. Prebiotics,
such as SlimBiome, may stimulate the body's natural gut hormones, providing a
gentler yet effective approach to appetite regulation. These findings align
with earlier trials demonstrating reduced food intake and cravings over a
four-week supplementation period."

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLGDLXDBDGUG